Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Name:
PIIS1470204517306228.pdf
Size:
510.2Kb
Format:
PDF
Description:
Full text, Open Access article
Authors
Seddon, BStrauss, S
Whelan, J
Leahy, Michael G
Woll, P
Cowie, F
Rothermundt, C
Wood, Z
Benson, C
Ali, N
Marples, M
Veal, G
Jamieson, D
Küver, K
Tirabosco, R
Forsyth, S
Nash, S
Dehbi, H
Beare, S
Affiliation
University College London Hospitals NHS Foundation Trust, London, UK.Issue Date
2017-10
Metadata
Show full item recordAbstract
For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma.Citation
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. 2017, 18 (10):1397-1410 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(17)30622-8PubMed ID
28882536Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(17)30622-8